Showing Results for
- Academic Journals (55)
Search Results
- 55
Academic Journals
- 55
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedMarc Tessier-Lavigne has been named to the board of directors of Agios Pharmaceuticals (Cambridge, MA, USA). He is currently president of The Rockefeller University in New York and formerly served as executive vice...
- 2From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedDramatic pilot study results describing an engineered T-cell cancer treatment have given the adoptive cellular immunotherapy field a much-needed boost. In simultaneously published papers from a group at the University of...
- 3From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedOn August 19, Seattle Genetics of Bothell, Washington, received the nod from the US Food and Drug Administration (FDA) for its immunoconjugate drug Adcetris (brentuximab vedotin) in two rare cancers, relapsing Hodgkins...
- 4From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedFor eukaryotes, synthetic biologists have created individual genes or pathways but not entire genomes. Dymond et al. take a step towards achieving the latter with a paper in Nature that describes the first synthetic...
- 5From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedIn August, Somaxon Pharmaceuticals chose an alternative strategy to raise $30 million, and in June, BioCryst Pharmaceuticals of Research Triangle Park, North Carolina, used a similar tactic to raise $70 million. Both...
- 6From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedClassic experiments such as somatic cell nuclear transfer into oocytes and cell fusion demonstrated that differentiated cells are not irreversibly committed to their fate. More recent work has built on these conclusions...
- 7From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedAdrian Adams has been appointed chairman and CEO, and Andrew I. Koven has been named president and chief administrative officer of Neurologix (Fort Lee, NJ, USA). Both Adams and Koven also join the company's board of...
- 8From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedRecent patent applications in drug screening Patent number Description WO 2011096230 A magnetic particle-containing medicinal formulation useful for delivering and screening drugs, and separating and purifying nucleic...
- 9From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedDisentangling cellular heterogeneity is a challenge in many fields, particularly in the stem cell and cancer biology fields. Here we demonstrate how to combine viral genetic barcoding with high-throughput sequencing to...
- 10From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedIt would be nice if all the stars aligned to benefit your business and product development plans, but that is almost never the case. There is usually some kind of hurdle: a difficult regulatory path, a challenging...
- 11From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedA regional research center to promote and disseminate new agricultural research and technology in the region becomes operational. The Centre for Coordination of Agricultural Research and Development for Southern Africa...
- 12From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedThe recent development of super-resolution fluorescence microscopy techniques has shattered the longstanding resolution barrier of ~200 nm imposed by the diffraction of light. Whereas conventional fluorescence imaging...
- 13From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedGilead Sciences and the Geneva-based Medicines Patent Pool (MPP) have entered into an agreement allowing manufacturers to produce low-cost versions of the biotech firm's HIV drugs. Gilead's Viread (tenofovir), Emtriva...
- 14From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedWhole genome amplification by the multiple displacement amplification (MDA) method allows sequencing of DNA from single cells of bacteria that cannot be cultured. Assembling a genome is challenging, however, because MDA...
- 15From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedFive Prime Therapeutics (S. San Francisco, CA, USA) has announced the election of Peder K. Jensen to its board of directors. Jensen most recently served as corporate senior vice president and general manager, R&D for...
- 16From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedIn direct lineage conversion, a differentiated cell is converted to another type of differentiated cell through forced expression of a small number of transcription factors. This approach has been used to turn mouse and...
- 17From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedThe government enters a collaboration with French chemical producer ARKEMA and South Korea's CheilJedang to build a plant producing biomethionine, a sulphur amino acid used in animal feed production. The ten-year, $667...
- 18From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedThe US Food and Drug Administration continued to approve drugs at a faster pace than during the same time last year. Small molecules were particularly prominent, including Roche's B-RAF V600E mutation-specific Zelboraf...
- 19From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedThe ability of monoclonal antibodies (mAbs) specific for CD40, a member of the tumor necrosis factor receptor (TNFR) family found on antigen-presenting cells (APCs), to induce antitumor immunity has until now been...
- 20From: Nature Biotechnology. (Vol. 29, Issue 10) Peer-ReviewedA new collaborative program to ready the UK's National Health Service (NHS) for personalized cancer care is underway. The 5.5 million [sterling pounds] ($8.7) Stratified Medicine Programme, led by the charity Cancer...